ResApp Health (ASX:RAP) achieves CE mark for sale of device in Europe

Company News

by Rachael Jones

Digtal health company ResApp Health (ASX:RAP) has achieved CE Mark certification for the company’s wearable device as a Class I medical device accessory.

This allows ResApp to progress the manufacture and sale of the device in Europe.

ResApp’s wearable device allows for continuous 24-hour patient monitoring using cough audio.

Cough frequency is a key factor in respiratory disease progression and management, and may be an important outcome measure in clinical trials involving a broad range of disease states where cough is implicated.

Shares in ResApp Health (ASX:RAP) are trading 1.8 per cent higher at 6 cents.

 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.